"シオノギ製薬" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonCumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Custom...
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High - Still a Buy? - Mark...
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High - Still a Buy? MarketBeat
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi Inc.
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 Shionogi Inc.
Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum...
Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum Yahoo Finance
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV - DCAT Value Ch...
Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV DCAT Value Chain Insights
Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release - lupin.com
Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release lupin.com
Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake - Bloomberg.com
Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake Bloomberg.com
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up Pharmaceutical Technology
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - Europ...
[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding European AIDS Treatment Group
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - GSK
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding GSK
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake Reuters
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive
Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer Pharmaceutical Executive
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - B...
Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share BioXconomy
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused ...
Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company Fierce Pharma
Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts - si...
Results: Shionogi & Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts simplywall.st
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADI...
Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA Cleary Gottlieb
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation Shionogi Inc.
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership Yahoo Finance
All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy - Yahoo Finance
All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy Yahoo Finance
Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And Wha...
Why Shionogi (TSE:4507) Is Up 6.2% After Profit Growth Outpaced Sales In Latest Results – And What's Next Yahoo Finance
Pfizer Cashes In ViiV Stake With Shionogi Sale For $1.88bn - Citeline News & Insights
Pfizer Cashes In ViiV Stake With Shionogi Sale For $1.88bn Citeline News & Insights
Shionogi & Co. (SGIOF) Price Target Increased by 19.88% to 20.86 - Nasdaq
Shionogi & Co. (SGIOF) Price Target Increased by 19.88% to 20.86 Nasdaq
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma
Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal FirstWord Pharma
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld MedTech
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more BioWorld MedTech
Pfizer sells ViiV stake to Shionogi - The Pharma Letter
Pfizer sells ViiV stake to Shionogi The Pharma Letter
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierc...
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business Fierce Pharma
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Issues Quarterly Earnings Results, Beats Est...
Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty incom...
Shionogi & Co: Strong revenue and profit growth, boosted by acquisitions and robust royalty income TradingView
Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug - BioP...
Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug BioPharma Dive
Shionogi to buy Jersey City pharma for $2.5B - NJBIZ
Shionogi to acquire ALS medications from Tanabe - The Pharma Letter
Shionogi to acquire ALS medications from Tanabe The Pharma Letter
Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug - FirstWord Pharma
Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug FirstWord Pharma
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma...
ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma
ALS med Radicava to change hands as Shionogi inks $2.5B buyout Fierce Pharma
Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today
Shionogi moves to acquire global rights to Radicava for ALS ALS News Today
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma
Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance Fierce Pharma
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Fi...
Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain Yahoo Finance
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook - TipRanks
Shionogi Delivers Double-Digit Profit Growth and Confirms FY2026 Outlook TipRanks
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP Infectious Disease Special Edition
Can Shionogi’s Rally Continue After Key Drug Approval in 2025? - Yahoo Finance
Can Shionogi’s Rally Continue After Key Drug Approval in 2025? Yahoo Finance
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - WTVB
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits WTVB
Shionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion - TipRanks
Shionogi Lifts Revenue and Profit on Royalty Growth and Overseas Expansion TipRanks
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact - BioWorld MedTech
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact BioWorld MedTech
Enrollment Update - Shionogi Inc.
Enrollment Update Shionogi Inc.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume - What's ...
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - TradingView
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake TradingView
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - MSN
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake MSN
Shionogi to increase stake in ViiV Healthcare as Pfizer exits - Investing.com
Shionogi to increase stake in ViiV Healthcare as Pfizer exits Investing.com
Recon: FDA approves Cytokinetics’ heart drug in first for drugmaker; Shionogi forges $2.5 billion...
Recon: FDA approves Cytokinetics’ heart drug in first for drugmaker; Shionogi forges $2.5 billion buyout of Tanabe Pharma’s ALS therapy Radicava Regulatory Affairs Professionals Society | RAPS
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare BioSpectrum Asia
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake - Endpoints News
Pfizer to depart GSK’s ViiV as Shionogi doubles its stake Endpoints News
Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahea...
Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahead Smartkarma
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge JAPAN Forward
BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology
BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology
GSK and Shionogi Restructure Stake in ViiV Healthcare - GuruFocus
GSK and Shionogi Restructure Stake in ViiV Healthcare GuruFocus
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Custom...
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. The Malaysian Reserve
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...
Shionogi inks hearing loss deal with Salubritas Therapeutics - The Pharma Letter
Shionogi inks hearing loss deal with Salubritas Therapeutics The Pharma Letter
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug - MarketWatch
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug MarketWatch
Shionogi expands rare disease presence with acquisition of global rights to Tanabe’s RADICAVA for...
Shionogi expands rare disease presence with acquisition of global rights to Tanabe’s RADICAVA for $2.5 B BioSpectrum Asia
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program Fierce Biotech
Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial -...
Shionogi’s Oral RSV Antiviral Moves Forward: What Investors Should Watch in This Phase 2b Trial TipRanks
Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma
Shionogi strikes research and option deal with BioVersys for antibacterial assets FirstWord Pharma
Japan's Shionogi pays $2.13B to boost stake in ViiV Healthcare - Latest news from Azerbaijan
Japan's Shionogi pays $2.13B to boost stake in ViiV Healthcare Latest news from Azerbaijan
Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits - Indian Pharma Post
Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits Indian Pharma Post
Shionogi lifts profit outlook on HIV royalties and overseas growth - The Japan Times
Shionogi lifts profit outlook on HIV royalties and overseas growth The Japan Times
Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture - TipRanks
Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture TipRanks
Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum
Shionogi puts up to $600m behind BioVersys antibiotics pharmaphorum
Shionogi’s Fetroja launches in Japan - The Pharma Letter
Shionogi’s Fetroja launches in Japan The Pharma Letter
BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter
BioVersys joins forces with Shionogi on ansamycin development The Pharma Letter
GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes By Investing.com - Investi...
GSK, Pfizer and Shionogi agree on ViiV Healthcare shareholding changes By Investing.com Investing.com Nigeria
Gareth Morgan Named President of Qpex Biopharma, Inc. - Business Wire
Gareth Morgan Named President of Qpex Biopharma, Inc. Business Wire
GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare - TipRanks
GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare TipRanks
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners Imperial College Healthcare NHS Trust
Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech
Bioversys, Shionogi in CHF529M lung infection collaboration BioWorld MedTech
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe - Citeline News & In...
Shionogi Expands Rare Disease Portfolio With $2.5bn Radicava Buy From Tanabe Citeline News & Insights
Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma
Shionogi to buy Japan Tobacco's pharma units for over $1B FirstWord Pharma
Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer - markets...
Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer marketscreener.com
Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter
Shionogi pushes 2030 vision forward with $1 billion acquisition The Pharma Letter
Yomiuri: Shionogi to Acquire ALS Drug Business from Tanabe Pharma for 2.5 Billion Dollars - Marke...
Yomiuri: Shionogi to Acquire ALS Drug Business from Tanabe Pharma for 2.5 Billion Dollars MarketWatch
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - Bloomberg Law News
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug Bloomberg Law News
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs Bloomberg.com
GSK and Shionogi Buy Out Pfizer’s Stake in HIV Specialist ViiV Healthcare - TipRanks
GSK and Shionogi Buy Out Pfizer’s Stake in HIV Specialist ViiV Healthcare TipRanks
Pfizer Sells ViiV Stake for USD 1.9 Billion, Shionogi Emerges Bigger Partner - Medical Dialogues
Pfizer Sells ViiV Stake for USD 1.9 Billion, Shionogi Emerges Bigger Partner Medical Dialogues
Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi - WV News
Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi WV News
Shionogi & Co.'s Nine-Month Profit Jumps 18% - 富途牛牛
Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter
Shionogi files in Japan to expand pediatric use of COVID-19 antiviral The Pharma Letter
Japan's Shionogi to raise stake in UK HIV drugmaker ViiV with $2.1bn investment - MLex
Japan's Shionogi to raise stake in UK HIV drugmaker ViiV with $2.1bn investment MLex
GSK, Pfizer, and Shionogi agree on ViiV Healthcare shareholding changes - marketscreener.com
GSK, Pfizer, and Shionogi agree on ViiV Healthcare shareholding changes marketscreener.com
Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy
Eyes on Asia: Chugai, Mabwell, Shionogi BioXconomy
Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech
Shionogi to acquire Japan Tobacco pharma companies for $1.1B BioWorld MedTech
Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia
Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs Nikkei Asia
Shionogi to increase stake in ViiV Healthcare as Pfizer exits By Investing.com - Investing.com So...
Shionogi to increase stake in ViiV Healthcare as Pfizer exits By Investing.com Investing.com South Africa
FDA will review ensitrelvir for COVID-19 prevention - Healio
Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum
Shionogi aims to buy tobacco giant's pharma unit for $1bn pharmaphorum
Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal - NJ.com
Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal NJ.com
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - ET Pharma
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake ET Pharma
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan Business Wire